Cytokine Release Syndrome Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

June 16 23:30 2021
Cytokine Release Syndrome Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cytokine Release Syndrome Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and multiple organ dysfunction that is associated with chimeric antigen receptor (CAR)-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients who are treated with immunotherapy and may or may not accompany Cytokine Release Syndrome.

Management of CRS includes monitoring and laboratory tests, treating specific symptoms, and medicines to lower the immune response. Treatments are based on the severity or grade of cytokine release syndrome. Children with more extensive diseases related to their cancer are at higher risk for more severe CRS. Till now there is only one therapy that is approved for Cytokine Release Syndrome, i.e., Actemra (tocilizumab). And apart from this therapy, the treatment also depends on the use of off-labeled drugs.

Get FREE sample copy at:

The Cytokine Release Syndrome Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Cytokine Release Syndrome market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Cytokine Release Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Cytokine Release Syndrome Market

Cytokine Release Syndrome Market Key Facts

  • The total number of patients who develop Cytokine Release Syndrome following CART therapies in the 7MM was 3,371 in 2020.

  • Among the European 5 countries, Germany had the highest population of Cytokine Release Syndrome with 199 cases, followed by  France and the United Kingdom with 175 and 161 cases respectively. On the other hand, Spain had the lowest population of 90 cases in 2020.

  • Japan had 217 cases of Cytokine Release Syndrome in 2020, with the approval of Kymriah.

  • The total number of Hematologic malignancies [includes ALL, B-Cell NHL (DLBCL, FL, PMBCL, etc.) & Multiple Myeloma] patients receiving CART-therapies in the 7MM were 4,389 in 2020.

Key Benefits of Cytokine Release Syndrome Market Report

  • Cytokine Release Syndrome market report provides an in-depth analysis of Cytokine Release Syndrome Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Cytokine Release Syndrome Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Cytokine Release Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Cytokine Release Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Cytokine Release Syndrome Market

Cytokine Release Syndrome (CRS) Market Size is anticipated to increase during the study period owing to the higher usage of CAR-T cell therapies in Hematological cancer patients across 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Cytokine Release Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

 The report gives a thorough detail of the Cytokine Release Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

Cytokine Release Syndrome Therapeutics Market

The rising usage of CAR-T cell therapies has prompting pharmaceutical companies to develop new therapies to prevent and treat Cytokine Release Syndrome in order to provide safe treatment options. As per DelveInsight, the Cytokine Release Syndrome market size is expected to increase during the forecast period owing to the launch of emerging therapies.

 Cytokine Release Syndrome Epidemiology

The epidemiology section covers insights about the historical and current Cytokine Release Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Cytokine Release Syndrome Epidemiology Segmentation – 

  • Total Number of B-cell NHL Patients receiving CAR T-Cell Therapies

  • Total Number of Acute lymphoblastic leukemia (ALL) Patients receiving CAR-T Cell Therapies

  • Total Number of Multiple Myeloma (MM) Patients receiving CAR-T Cell Therapies

  • Total Number of Patients developing Cytokine Release Syndrome (CRS) following CART therapies

  • Number of Patients Developing Cytokine Release Syndrome (CRS) by Severity/Grade

Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytokine Release Syndrome market or expected to get launched in the market during the study period. The analysis covers Cytokine Release Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Cytokine Release Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Cytokine Release Syndrome market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Cytokine Release Syndrome emerging therapies.

The rise in the incidence of Cytokine Release Syndrome stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable. Companies across the globe have shifted their focus toward the treatment of Cytokine Release Syndrome. The increase in the incidence will potentiate the Cytokine Release Syndrome treatment market.

Cytokine Release Syndrome Companies

  • Incyte Corporation

  • Jazz Pharmaceuticals

  • Sobi

And many others.

Cytokine Release Syndrome Therapies covered in the report include:

  • Itacitinib 

  • Defibrotide

  • Anakinra

And many more.

Along with this, various companies are developing technologically modified CAR-T cell therapies with limited reporting of Cytokine Release Syndrome as well as neurotoxicity as adverse events.

Table of Content

1. Key Insights

2. Executive Summary 

3. Cytokine Release Syndrome Competitive Intelligence Analysis

4. Cytokine Release Syndrome Market Overview at a Glance

5. Cytokine Release Syndrome Disease Background and Overview

6. Cytokine Release Syndrome Patient Journey

7. Cytokine Release Syndrome Epidemiology and Patient Population

8. Cytokine Release Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Cytokine Release Syndrome Unmet Needs

10. Key Endpoints of Cytokine Release Syndrome Treatment

11. Cytokine Release Syndrome Marketed Products

12. Cytokine Release Syndrome Emerging Therapies

13. Cytokine Release Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Cytokine Release Syndrome Market Outlook (7 major markets)

16. Cytokine Release Syndrome Access and Reimbursement Overview

17. KOL Views on the Cytokine Release Syndrome Market.

18. Cytokine Release Syndrome Market Drivers

19. Cytokine Release Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Healthcare Blogs
MedTech Industry Analysis

The MedTech industry is expected to witness growth owing to the introduction of smaller, cost-effective, wireless technologies, that along with better treatment will also ensure safety for both healthcare workers and patients. Some of the key MedTech Companies exploiting the domain and changing the market dynamics include Abbott, Medtronic, Zimmer Biomet, Johnson & Johnson, Boston Scientific, Olympus Corporation of the Americas, Smith & Nephew, Nevro, EXINI Diagnostics, and others. For more detailed information, visit: Leading MedTech Companies

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States